New treatment strategies against hepatitis C viral infection

Canadian Journal of Gastroenterology

Volumn 20, Issue 11, 2006, Pages 735-739

  Bilodeau, Marc ^a,b   Lamarre, Daniel ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE   (Canada)

Author keywords

Antivirals; Hepatitis C virus; Immunotherapy; Polymerase; Protease; Therapy

Indexed keywords

ALBUMIN ALPHA INTERFERON; ANTIVIRUS AGENT; CILUPREVIR; CPG 10101; CYCLOSPORIN; INTERFERON; ISATORIBINE; MERIMEPODIB; NUCLEOTIDYLTRANSFERASE INHIBITOR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAMIDINE; RIBAVIRIN; SCH 503034; THYMOSIN ALPHA1; VALOPICITABIN; VX 950;

ANEMIA; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MOLECULAR BIOLOGY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD; VIRUS MORPHOLOGY;

EID: 33845636037     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/863509     Document Type: Review

References (41)

1. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
2. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.
3. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
4. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon-α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8.
5. Katze MG, He Y, Gale M Jr. Viruses and interferon: A fight for supremacy. Nat Rev Immunol 2002;2:675-87.
6. Bain V, Kaita K, Yoshida E, et al. A phase 2 study to assess antiviral response, safety, and pharmacokinetics of Albuferon in IFN-α naive subjects with genotype 1 chronic hepatitis C. J Hepatol 2005;42(Suppl 2):9A. (Abst)
7. Manns MP, Berg T, Wedemeyer H, et al. Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients. Hepatology 2004;40(Suppl 1):251A. (Abst)
8. Wedemeyer H, Berg T, Manns MP, et al. Induction of TH1/TC1 type immunity in chronic hepatitis C non-responder patients with the therapeutic peptide vaccine IC41. J Hepatol 2005;42(Suppl 2):9A-10A. (Abst)
9. Horsmans Y, Brenard R, Starkel P, et al. Tolerability and immunogenicity of HCV E1 therapeutic vaccination in patients with chronic hepatitis C on interferon plus ribavirin. J Hepatol 2005;42(Suppl 2):207A. (Abst)
10. Di Bisceglie A, Frey S, Gorse GJ, et al. A phase I safety and immunogenicity trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults. Hepatology 2005;42(Suppl 1):750A. (Abst)
11. Finlay BB, Hancock RE. Can innate immunity be enhanced to treat microbial infections? Nat Rev Microbiol 2004;2:497-504.
12. Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005;42:724-31.
13. McHutchison J, Bacon B, Gordon SC, et al. Relationships of HCV RNA responses to CPG 10101, a TLR9 agonist: Pharmacodynamics and patient characteristics. Hepatology 2005;42(Suppl 1):249A. (Abst)
14. Bacon BR, McHutchison JG, Gordon SC, et al. Safety, pharmacodynamic and pharmacokinetic profiles of CPG 10101 (Actilon-TM), a novel TLR-9 agonist: Comparison in normal volunteers and HCV infected individuals. Gastroenterology 2005;128(Suppl 2):696A. (Abst)
15. Andreone P, Gramenzi A, Cursaro C, et al. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: Results of a randomized controlled pilot trial. J Viral Hepat 2004;11:69-73.
16. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
17. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.
18. Lin CC, Yeh LT, Vitarella D, Hong Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 2003;14:145-52.
19. Gish RG, Nelson D, Arora S, et al. Virologic response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon α-2a. J Hepatol 2005;42(Suppl 2):39A. (Abst)
20. Zha J, Garg V, McNair L, et al. Pharmacokinetic-pharmacodynamic relationships of merimepodib and ribavirin in pegylated interferon-alfa/ ribavirin/merimepodib treated genotype-1 HCV patients non-responsive to previous therapy with interferon-alfa/ribavirin. Hepatology 2004;40(Suppl 1):250A. (Abst)
21. Wainberg MA, Dascal A, Blain N, et al. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood 1988;72:1904-10.
22. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-8.
23. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: Controlled trial. J Gastroenterol 2003;38:567-72.
24. Lin K, Ma S, Boemer J, et al. NIM811 exhibits potent anti-HCV activity in vitro and represents a novel approach for viral hepatitis C therapy. Hepatology 2005;42(Suppl 1):536A. (Abst)
25. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: Unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat 1999;6:165-81.
26. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9.
27. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347-55.
28. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005;41:832-5.
29. Thibeault D, Bousquet C, Gingras R, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 2004;78:7352-9.
30. Reesink HW, Zeuzem S, Weegink CJ, et al. Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 2005;42(Suppl 1):234A-5A. (Abst)
31. Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 patients refractory to pegylated interferon. Hepatology 2005;42(Suppl 1):233A-4A. (Abst)
32. Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus PEG-INTRON in hepatitis C genotype-1 PEG-INTRON non-responders: Phase IB results. Hepatology 2005;42(Suppl 1):276A-7A. (Abst)
33. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280:36784-91.
34. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006. (In press)
35. Sarrazin C, Kieffer T, Bartels D, et al. Characterization of viral variants in the HCV NS3 protease domain of genotype 1 patients that are selected during 14 days of dosing with VX-950. Hepatology 2005;42(Suppl 1):751A. (Abst)
36. Afdhal N, Rodriguez-Torres M, Lawitz E, et al. Enhanced antiviral efficacy for valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype-1 infection: Results of a phase IIa multicenter trial. J Hepatol 2005;42(Suppl 2):39A-40A. (Abst)
37. Rodriguez-Torres M, Lawitz E, Godofsky E, et al. Valopicitabine (nm 283) alone and in combination with Peg-Interferon in patients with genotype 1 chronic hepatitis C: Preliminary results from an ongoing phase II, multicenter study. Gastroenterology 2005;128(4 Suppl 2):695A-6A. (Abst)
38. Zhou XJ, Afdhal N, Godofsky E, et al. Pharmacokinetics and pharmacodynamics of valopicitabine (nm283), a new nucleoside Hcv polymerase inhibitor: Results from a Phase I/ii dose-escalation trial in patients with Hcv-1 infection. Gastroenterology 2005;128(Suppl 2):700A. (Abst)
39. O'Brien C, Godofsky E, Rodriguez-Torres M, et al. Randomized trial of valopicitabine (NM 283), alone or with PEG-interferon, vs retreatment with PEG-interferon plus ribivirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN/RBV: First interim results. Hepatology 2005;42(Suppl 1):234A. (Abst)
40. Tong M, Schiff E, Jensen DM, et al. Preliminary analysis of a phase II study of Heptazyme, a nuclease resistant ribozyme targeting hepatitis C virus RNA. Hepatology 2002;36:360A. (Abst)
41. Gordon SC, Bacon BR, Jacobson IM, et al. A phase II, 12-week study of ISIS 14803, an anti-sense inhibitor of HCV for the treatment of chronic hepatitis C. Hepatology 2002;36:362A. (Abst)